Forbion Capital Partners

ALGEMENE INFORMATIE

Bezoekadres
Gooimeer 2-35
1411 DC Naarden

Postadres
Postbus 5187
1410 AD Naarden

Tel: 035 699 30 00
Fax: 035 699 30 01
Contactpersoon
V. van Houten
Directie
S.J.H. van Deventer, G.J. Mulder, M.A. van Osch, H.A. Slootweg
  • BEKIJK DE WEBSITE
Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages six closed-end funds with commitments exceeding EUR 700m, including its $200m+ FCFIII fund, launched in 2016. Forbion is actively looking for new, exciting opportunities in Europe and North America. To this end Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s underlying portfolio theme is investing in private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. Forbion helps such companies to bridge research and development, not just financially via its six funds, but also through its team members’ expertise. Its current portfolio comprises around 27 active investments in companies working on a range of globally important disease areas of high (unmet) medical need. Portfolio companies are typically working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system, pain management and the microbiome. Recent examples of successful investments include Dezima Pharma sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures). Forbion also operates a joint venture with BioGeneration Ventures, who manage three separate seed and early stage funds focused on Benelux.

BioGeneration Ventures manage funds that are actively investing venture capital in the next generation of successful Biotech companies in Europe with a focus on The Netherlands, Belgium and Germany. BioGeneration focuses on high- potential companies active in therapeutics, medical devices, and diagnostics areas. The team of BioGeneration Ventures has a successful track record and broad experience in the life sciences sector. Its involvement goes beyond a mere financial investment. Having worked in both the startup environment as well as established industry players BioGeneration’s strategy is to generate value by working very closely with its portfolio companies and provide active hands-on support. BioGeneration has achieved numerous successful exits and has shown a very strong fund performance. On 1 July 2016, BioGeneration had a first closing of its third Fund BGV III from which it is currently investing.
Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages six closed-end funds with commitments exceeding EUR 700m, including its $200m+ FCFIII fund, launched in 2016. Forbion is actively looking for new, exciting opportunities in Europe and North America. To this end Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s underlying portfolio theme is investing in private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. Forbion helps such companies to bridge research and development, not just financially via its six funds, but also through its team members’ expertise. Its current portfolio comprises around 27 active investments in companies working on a range of globally important disease areas of high (unmet) medical need. Portfolio companies are typically working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system, pain management and the microbiome. Recent examples of successful investments include Dezima Pharma sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures). Forbion also operates a joint venture with BioGeneration Ventures, who manage three separate seed and early stage funds focused on Benelux.

BioGeneration Ventures manage funds that are actively investing venture capital in the next generation of successful Biotech companies in Europe with a focus on The Netherlands, Belgium and Germany. BioGeneration focuses on high- potential companies active in therapeutics, medical devices, and diagnostics areas. The team of BioGeneration Ventures has a successful track record and broad experience in the life sciences sector. Its involvement goes beyond a mere financial investment. Having worked in both the startup environment as well as established industry players BioGeneration’s strategy is to generate value by working very closely with its portfolio companies and provide active hands-on support. BioGeneration has achieved numerous successful exits and has shown a very strong fund performance. On 1 July 2016, BioGeneration had a first closing of its third Fund BGV III from which it is currently investing.  

PROFIEL

  • Sectoren/branches
  • Life Sciences
  • Financieringsfasen
  • Expansie / groei
  • Seed
  • Start
  • Investering
  • 250.000 - 2 mln
  • 2 mln - 5 mln
  • 5 mln - 20 mln
  • Regio's
  • Benelux
  • Duitsland
  • Europa
  • Nederland
  • Belegger in fonds
  • Institutioneel
#
#

NVP (Geassocieerde) leden

  • NPM Capital N.V.
  • JSA Tax Consultancy B.V.
  • Atlantic Capital B.V.
  • Tauw Group B.V.
  • PPM Oost
  • MBCF B.V.
  • AlpInvest Partners B.V.
  • IBS Capital Allies
  • Health Innovations
  • Gilde Healthcare
  • Bridgepoint Capital Ltd
  • HPE Growth Capital
  • AKD
  • HB Capital
  • Vendis Capital
  • Advent International
  • Egeria
  • Clifford Chance
  • Legadex B.V.
  • Port4Growth
  • Vondel Finance B.V.
  • SEAM Investments
  • StartGreen Capital
  • Rabo Private Equity
  • ERM
  • NautaDutilh
  • Main Capital Partners B.V.
  • Van Reekum Participatie Fonds
  • Houthoff Buruma N.V.
  • Parcom Capital Management B.V.
  • Ogomar BV
  • Freshfields Bruckhaus Deringer LLP
  • Delft Enterprises B.V.
  • Rabobank Corporate Finance Advisory
  • Jones Day
  • Van Campen Liem
  • SINCERIUS Transaction Services
  • IRIS Corporate Finance B.V.
  • Benvalor Advocaten & Belastingadviseurs
  • Chemelot Ventures
  • Prime Ventures
  • Meijburg & Co
  • Navitas Capital
  • Oranje-Nassau Participaties B.V.
  • Alvarez & Marsal
  • Capitalmind, Corporate Finance Advisory
  • NBI Investors
  • Kohlberg Kravis Roberts & Co Partners LLP (KKR)
  • DVAN Advocatuur & Notariaat
  • Chubb Insurance Company of Europe
  • Allen & Overy LLP
  • The Gap Partnership Netherlands B.V.
  • Indofin Group
  • Bain & Company
  • KPMG Transaction Services
  • DLA Piper Nederland N.V.
  • Holland Venture Management B.V.
  • TransEquity Network B.V.
  • Aon Stratigic Advisors & Transaction Solutions
  • DFZ Participaties B.V.
  • OOK, Ondernemend Oranje Kapitaal
  • Cinven Limited
  • Gilde Equity Management Benelux
  • De Brauw Blackstone Westbroek
  • Brainport Development N.V.
  • AAC Benelux Holding B.V.
  • Custom Management
  • Committed Capital Management
  • Xattu
  • Lebrowsky B.V.
  • InvestInFuture
  • Accuracy Netherlands B.V.
  • Invest Europe
  • ABN AMRO Participaties
  • Chestnut Corporate Finance
  • Informal Capital Network B.V. (ICN)
  • Linklaters LLP
  • CVC Capital Partners
  • Spring Associates B.V.
  • KplusV
  • 5square
  • Stibbe
  • InnovationQuarter
  • Gilde Buyout Partners
  • Mentha Capital
  • CORP.
  • Forbion Capital Partners
  • Grant Thornton Specialist Advisory Services B.V.
  • Wadinko N.V.
  • SET Ventures
  • Karmijn Kapitaal
  • Kneppelhout & Korthals Advocaten
  • PhiDelphi Corporate Finance
  • UNO bedrijfsadviseurs B.V.
  • Willis Towers Watson
  • Euronext
  • BDO Corporate Finance B.V.
  • Avedon Capital Partners B.V.
  • Active Capital Company B.V.
  • De Hoge Dennen
  • Blacktrace B.V.
  • Amstone Tax Lawyers
  • MKB Fonds Flevoland en Technofonds Flevoland
  • Loyens & Loeff
  • Gimv
  • Value Enhancement Partners
  • Van Doorne N.V.
  • Cataly Partners B.V.
  • CorporateWise
  • NIBC Mezzanine & Equity Partners
  • Van Lanschot Participaties
  • Plain Vanilla Investments BV
  • NCB Participaties B.V.
  • Aeternus B.V.
  • O2 Capital Partners B.V.
  • Brabantse Ontwikkelings Maatschappij (BOM)
  • Kröller Boom Assurantiën B.V.
  • Michael Page International B.V.
  • Deloitte M&A
  • PricewaterhouseCoopers (PwC)
  • Claassen,Moolenbeek&Partners
  • VP Participaties
  • Thuja Capital
  • EY, Transaction Advisory Services
  • Nordian Capital Partners
  • Ebbinge
  • ATAIR Company
  • Mazars Financial Advisory Services
  • Kennedy Van der Laan
  • Teslin Capital Management BV
  • Hogan Lovells International LLP
  • Kamer van Koophandel
  • Levine Leichtman Capital Partners
  • Marsh Private Equity and M&A Practice
  • KNHM Participaties B.V.
  • Simmons & Simmons
  • KroeseWevers Corporate Finance B.V.
  • Waterland Private Equity Investments B.V.
  • Antea Participaties
  • 3i Europe plc Benelux
  • Olym Advocaten
  • N.V. NOM
  • EQT Partners AB, Dutch Branch
  • Synergia Capital Partners B.V.
  • Lexence
  • Riverside Europe Partners Sprl
  • Strong Root Capital
  • Ten Kate Huizinga Corporate Finance
  • Baker & McKenzie Amsterdam N.V.
  • KPMG Corporate Finance
  • Atlas Fiscalisten N.V.
  • Renoir Capital Partners
  • Nielen Schuman B.V.
  • YESS International Consultants
  • Dolfin Capital
  • Eversheds
  • Industriebank LIOF
  • The Executive Network
  • TIIN Capital
  • LSP
  • Ecart Invest
  • De Breij Evers Boon